Nivolumab (NIVO) plus ipilimumab (IPI) vs lenvatinib (LEN) or sorafenib (SOR) as first-line treatment for unresectable hepatocellular carcinoma (uHCC): First results from CheckMate 9DW.
#4PRI RANKED
Most Cited Paper
in Hepatocellular Carcinoma Treatment and Prognosis
18 Months Post-Publication
Class of 2026
“Nivolumab (NIVO) plus ipilimumab (IPI) vs lenvatinib (LEN) or sorafenib (SOR) as first-line treatment for unresectable hepatocellular carcinoma (uHCC): First results from CheckMate 9DW.”
A research intelligence initiative by Pepkio
pri.pepkio.com/top-papers/hepatocellular-carcinoma-treatment-and-prognosis/2026/
Topics
nivolumab · ipilimumab · lenvatinib · sorafenib · Unresectable hepatocellular carcinoma · First-line treatment · CheckMate 9DW · Overall survival · Objective response rate · Duration of response · PD-1/PD-L1 inhibitor · CTLA-4 inhibition · immune checkpoint inhibitor combination · phase 3 randomized clinical trial · RECIST 1.1 · blinded independent central review · Complete response · Treatment-related adverse events · Child-Pugh class · Performance status · CheckMate 040 · PD-L1 expression · standard of care · interim analysis · hazard ratio · Durable response · Curative surgery · Locoregional therapy · Progressive disease · accelerated approval
Share
Cite this ranking
Pepkio Research Index (PRI). Topics and Trends in Most Cited Hepatocellular Carcinoma Treatment and Prognosis Papers, Class of 2026. https://pri.pepkio.com/top-papers/hepatocellular-carcinoma-treatment-and-prognosis/2026. Accessed 2026-07-13. Zheng Su, Tinsley Li, Thematic Shifts in Early-High-Impact Cancer Genomics and Diagnostics Research: A Bibliometric and Semantic Analysis. bioRxiv 2026.07.04.736459; doi: https://doi.org/10.64898/2026.07.04.736459